Altwairgi AK. Statins are potential anticancerous agents. Oncol. Rep., 33, 1019-1039 (2015)
Amelio I, Melino G. The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression. Trends Biochem. Sci., 40, 425-34 (2015).
Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol., 2, a000935 (2010)
Bieging KT, Mello SS, Attardi LD. Unraveling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer, 14, 359-370 (2014)
Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer, 6, 506-20 (2006)
Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell, 2, 456-462 (2011)
Campisi J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol., 75, 685–705 (2013)
Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. p53 on the crossroad between regeneration and cancer. Cell Death Differ., 24, 8–14 (2017)
Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. Lancet, 394, 793-804 (2019)
Chen Y, Di C, Zhang X, Wang J, Wang F1, Yan JF1, Xu C, Zhang J, Zhang Q, Li H, Yang H, Zhang H. Transforming growth factor β signaling pathway: A promising therapeutic target for cancer. J. Cell. Physiol., 235, 1903-1914 (2019)
Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: Dueling or complementary cell fates? EMBO Rep., 15, 1139–1153 (2014)
Choi YK, Yoon BI, Kook YH, Won YS, Kim JH, Lee CH, Hyun BH, Oh GT, Sipley J, Kim DY. Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice. Jpn. J. Cancer Res., 93, 151–156 (2002)
Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell, 113, 301–314 (2003)
Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S. The Hippo transducer TAZ confers cancer stem cell‐related traits on breast cancer cells. Cell, 147, 759–772 (2011)
Czekay RP, Wilkins-Port CE, Higgins SP, Freytag J, Overstreet JM, Klein RM, Higgins CE, Samarakoon R, Higgins PJ. PAI-1: An Integrator of Cell Signaling and Migration. Int. J. Cell Biol., 2011, 562481 (2011)
Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J., 17, 3091–3100 (1998).
Derynck R. Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature, 425, 577–584 (2003).
Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat. Rev. Cancer, 9, 587-95 (2009)
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817–825 (1993)
Escoll M, Gargini R, Cuadrado A, Anton IM, Wandosell F. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene, 36, 3515–3527 (2017)
Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev., 12, 2153–2163 (1998)
Furth N, Aylon Y, Oren M. p53 shades of Hippo. Cell Death Differ., 25, 81–92 (2018)
Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell, 134, 62-73 (2008)
Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90, 595–606 (1997)
Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature, 387, 819–823 (1997)
Huang S, Hölzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, Neefjes J, Salazar R, Ten Dijke P, Uramoto H, Tanaka F, Beijersbergen RL, Wessels LF, Bernards R. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell, 151, 937–950 (2012)
Ikushima H, Miyazono K. Cellular context-dependent “colors” of transforming growth factor-beta signaling. Cancer Sci., 101, 306–312 (2010)
Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev., 12, 2114–2119 (1998)
Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG, Lee S, Maher CA, Weiss SJ, Yook JI. A p53/miRNA-34 axis regulates Snail1- dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol., 195, 417–433 (2011)
Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol., 8, 888– 884 (2006)
Kortlever RM, Nijwening JH, Bernards R. Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J. Biol. Chem., 283, 24308– 24313 (2008)
Kruse JP, Gu W. Modes of p53 regulation. Cell, 137, 609–622 (2009)
Kunz C, Pebler S, Otte J, von der Ahe D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nuc.Acid Res., 23, 3710–3717 (1995)
Laptenko O, Beckerman R, Freulich E, Prives C. p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proc. Natl. Acad. Sci., 108, 10385–10390 (2011)
Larisch-Bloch S, Yarom R, Sulitzeanu D. Degenerative changes in the A375 melanoma line induced by transforming growth factor beta 1. Immunol. Lett., 33, 151-156 (1992)
Lee JY, Kim HJ, Yoon NA, Lee WH, Min YJ, Ko BK, Lee BJ, Lee A, Cha HJ, Cho WJ, Park JW. Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cells. Nuc. Acids Res., 41, 5614–5625 (2013)
Liu C, Huang W, Lei W. Regulation and function of the TAZ transcription co-activator. Int. J. Biochem. Mol. Biol., 2, 247–256 (2011)
Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell, 3, 577–587 (2003)
Massagué J. TGFβ signalling in context. Nat. Rev. Mol. Cell. Biol., 13, 616–630 (2012)
Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int. J. Cancer, 140, 1068–1081 (2017)
Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol., 127, 2021–2036 (1994)
Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 85, 314-23 (2009)
Nagata M, Goto K, Ehata S, Kobayashi N, Saitoh M, Miyoshi H, Imamura T, Miyazawa K, Miyazono K. Nuclear and cytoplasmic c-Ski differently modulate cellular functions. Genes Cells, 11, 1267–1280 (2006)
Noguchi S, Saito A, Nagase T. YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer. Int. J. Mol. Sci., 19, 3674 (2018)
Ogawa K, Chen F, Kim YJ, Chen Y. Transcriptional regulation of tristetraprolin by transforming growth factor-beta in human T cells. J. Biol. Chem., 278, 30373–30381 (2003)
Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 10, 431–442 (2003)
Overstreet JM, Samarakoon R, Meldrum KK, Higgins PJ. Redox control of p53 in the transcriptional regulation of TGF-β1 target genes through SMAD cooperativity. Cell. Signal., 26, 1427–1436 (2014)
Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol. Rev., 94, 1287–1312 (2014)
Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol., 9, 402–412 (2008).
Ross CR, Brennan-Laun SE, Wilson GM. Tristetraprolin: roles in cancer and senescence. Ageing Res. Rev., 11, 473–484 (2012)
Schneider G, Krämer OH. NFκB/p53 crosstalk-a promising new therapeutic target. Biochim. Biophys. Acta, 1815, 90-103 (2011)
Seoane J, Le HV, Shen L, Anderson SA, Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell, 117, 211–223 (2004)
Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer, 3, 807–821 (2003)
Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, Rosato A, Piccolo S, Del Sal G. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol., 16, 357–366 (2014)
Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, Blandino G. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol. Cell, 18, 447–459 (2005)
Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 508, 118–122 (2014)
Takebayashi-Suzuki K, Funami J, Tokumori D, Saito A, Watabe T, Miyazono K, Kanda A, Suzuki A. Interplay between the tumor suppressor p53 and TGF beta signaling shapes embryonic body axes in Xenopus. Development, 130, 3929–3939 (2003)
Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell, 133, 612-26 (2008)
Termén S, Tan EJ, Heldin CH, Moustakas A. p53 regulates epithelial-mesenchymal transition induced by transforming growth factor β. J. Cell Physiol., 228, 801–813 (2013)
Toledo F, Wahl GM. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer, 6, 909–923 (2006)
Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology, 110, 375– 382 (1996)
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small- molecule antagonists of MDM2. Science, 303, 844–848 (2004)
Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2, 594-604 (2002)
Wikström P, Stattin P, Franck-Lissbrant I, Damber J E, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate, 37, 19–29 (1998)
Wrana JL. Signaling by the TGFβ superfamily. Cold Spring Harb. Perspect. Biol., 5, a011197 (2013)
Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci, 36, 422-439 (2015)
Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC, Lu KP. Sequence-specific and phosphorylation- dependent proline isomerization: A potential mitotic regulatory mechanism. Science, 278, 1957–1960 (1997)
Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell, 163, 811–828 (2015)
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell, 29, 783–803 (2016)
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol., 3, 973-892 (2001)
Zhou X, Lei QY. Regulation of TAZ in cancer. Protein Cell, 7, 548–561 (2016)
Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat. Rev. Cancer, 16, 467–478 (2016)
論文の公開元へ
